Evidence map›Paper›PMID 35641198›Full record

Trial reportThe oncologist2022

Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance).

Seohyuk Lee, Chao Ma, Sui Zhang, Fang-Shu Ou, Tiffany M Bainter, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Renaud Whittom, Alexander Hantel and 7 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00003835 (Phase III Intergroup Trial of Irinotecan), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00003835 phase3completednot on this map

Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran1999Enrolled1,260ConditionsAdenocarcinoma of the Colon, Stage III Colon CancerArmsleucovorin calcium, fluorouracil, irinotecan hydrochloride, laboratory biomarker analysis
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Risk factors associated with the co-occurrence of severe pain and sleep disturbance in oncology outpatients receiving chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  5. Article
  6. Article
  7. Adherence to World Cancer Research Fund/American Institute for Cancer Research Guidelines and Mortality among Participants with Colorectal Cancer in the MEC.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 2 countries.

Seohyuk LeeYale School of Medicine, New Haven, CT, USA.ORCID 0000-0003-3023-1304
Chao MaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sui ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Fang-Shu OuAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-1267-8735
Tiffany M BainterAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.
Donna NiedzwieckiDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
Leonard B SaltzMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert J MayerDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA.
Renaud WhittomHôpital du Sacré-Coeur de Montréal, Montreal, Canada.
Alexander HantelLoyola University Stritch School of Medicine, Naperville, IL, USA.
Al BensonRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Daniel AtienzaVirginia Oncology Associates, Norfolk, VA, USA.
Hedy KindlerUniversity of Chicago Comprehensive Cancer Center, Chicago, IL, USA.ORCID 0000-0002-5450-842X
Cary P GrossYale School of Medicine, Department of Internal Medicine, New Haven, CT, USA.
Melinda L IrwinYale School of Public Health, New Haven, CT, USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA.
Charles S FuchsYale Cancer Center, Smilow Cancer Hospital and Yale School of Medicine, New Haven, CT, USA.
Yale University · USCancerCare · USDana-Farber Cancer Institute · USMayo Clinic · USDuke University · USHôpital du Sacré-Cœur de Montréal · CALoyola University Chicago · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · USUniversity of Chicago · USVirginia Oncology Associates · USYale Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Southeast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8M
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA149222NCI NIH HHS R01 CA169141NCI NIH HHS U10 CA138561NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA196171NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233320NCI NIH HHS UG1 CA233327NCI NIH HHS UG1 CA233337
6 · The paper itself

Abstract

backgroundLimited and conflicting findings have been reported regarding the association between social support and colorectal cancer (CRC) outcomes. We sought to assess the influences of marital status and living arrangement on survival outcomes among patients with stage III colon cancer. PATIENTS AND

methodsWe conducted a secondary analysis of 1082 patients with stage III colon cancer prospectively followed in the CALGB 89803 randomized adjuvant chemotherapy trial. Marital status and living arrangement were both self-reported at the time of enrollment as, respectively, married, divorced, separated, widowed, or never-married, and living alone, with a spouse or partner, with other family, in a nursing home, or other.

resultsOver a median follow-up of 7.6 years, divorced/separated/widowed patients experienced worse outcomes relative to those married regarding disease free-survival (DFS) (hazards ratio (HR), 1.44 (95% CI, 1.14-1.81); P =.002), recurrence-free survival (RFS) (HR, 1.35 (95% CI, 1.05-1.73); P = .02), and overall survival (OS) (HR, 1.40 (95% CI, 1.08-1.82); P =.01); outcomes were not significantly different for never-married patients. Compared to patients living with a spouse/partner, those living with other family experienced a DFS of 1.47 (95% CI, 1.02-2.11; P = .04), RFS of 1.34 (95% CI, 0.91-1.98; P = .14), and OS of 1.50 (95% CI, 1.00-2.25; P =.05); patients living alone did not experience significantly different outcomes.

conclusionAmong patients with stage III colon cancer who received uniform treatment and follow-up within a nationwide randomized clinical trial, being divorced/separated/widowed and living with other family were significantly associated with greater colon cancer mortality. Interventions enhancing social support services may be clinically relevant for this patient population.

trial registrationClinicalTrials.gov Identifier: NCT00003835.

Indexed as

Colonic NeoplasmsNeoplasm Recurrence, LocalChemotherapy, AdjuvantDisease-Free SurvivalHumansMarital Statusclinical trialcolonic neoplasmsmarital statusresidence characteristicssurvival analysis

Identifiers

PMID35641198
PMCPMC9177101
OpenAlexW4205259021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.